AnaCardio is a startup based in Sweden, most recent round Series A, 2 tracked investors.
Based in Sweden, AnaCardio is a startup founded in 2020. Its most recent tracked round is Series A. Brouky records 2 investors associated with the company.
AnaCardio is a clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, focusing on improving cardiac contractility through a unique mechanism based on the ghrelin signaling pathway.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.